Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Androgen Deprivation Therapy

Popular prostate cancer treatment associated with bone decay

Using novel technology allowing “virtual bone biopsies” researchers have found that a common treatment for prostate cancer called androgen deprivation therapy (ADT) is associated with structural decay of cortical and trabecular bone. The study has been accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM).

Prostate cancer is the… Popular prostate cancer treatment associated with bone decay   



Adding radiation to hormone therapy for prostate cancer treatment will increase survival chances

Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance of survival compared to patients who do not receive radiation, according to interim results of the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting… Adding radiation to hormone therapy for prostate cancer treatment will increase survival chances   



Short-term hormone therapy plus radiation therapy increases survival for men with early-stage prostate cancer

Short-term hormone therapy (androgen deprivation therapy: ADT) given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to a Radiation Therapy Oncology Group (RTOG) study published in… Short-term hormone therapy plus radiation therapy increases survival for men with early-stage prostate cancer   



PSA Drop Seen with New Prostate Cancer Drug

Half of a group of men with castration-resistant prostate cancer (CRPC) had biochemical responses to treatment with an investigational androgen receptor modulator, data from a preliminary clinical study showed.

During 12 weeks of treatment with galeterone, prostate-specific antigen (PSA) declined by at least 30% in 24 of 49 patients, 11 of whom had declines… PSA Drop Seen with New Prostate Cancer Drug   



Moffitt Cancer Center Researchers Find Genetic Predictors of Fatigue for Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Researchers at Moffitt Cancer Center and the University of South Florida have found that men with prostate cancer who receive androgen deprivation therapy may predictably suffer from fatigue if they have single nucleotide polymorphisms in three pro-inflammatory genes.  The discovery highlights the importance of personalized medicine, in which therapies are tailored to a patient’s… Moffitt Cancer Center Researchers Find Genetic Predictors of Fatigue for Prostate Cancer Patients Receiving Androgen Deprivation Therapy   



diabetic nephropathy6 - hemiuterus1 - bps1 - magnetic resonance imaging5 - vesicular stomatitis virus1 - hematuria8 - voiding dysfunction5 - sudden cardiac death2 - urethrotomy1 - hyperglycemia1 - urine leakage1 - aggregated disease groups1 - headache2 - european association of urology1 - hexagonal crystals1 - mri6 - creatinine2 - urethral anatomy3 - prostate-specific antigen test1 - urinary stones6 - urinary excretion1 - aspirin2 - lupus2 - urinary ions2 - renal tubules1 - cadmium toxicity1 - nuclear scintigraphy4 - yervoy1 - acute renal failure1 - food and drug administration1 -